What did Promisia Healthcare Limited announce?

Promisia Healthcare Limited (NZX: PHL) filed “PHL – Waivers from NZX Listing Rules 7.8.5(b) and 7.8.8(b)” with NZX on 13 August 2026, as a nzx compliance announcement.

When was it filed?
13 August 2026
Where is the original?
NZX announcement
Promisia Healthcare Limited logo

PHL – Waivers from NZX Listing Rules 7.8.5(b) and 7.8.8(b)

NZX Compliance13 August 2026PHLHealthcare

NZ RegCo

0



13 August 2026

NZ RegCo Decision

Promisia Healthcare Limited (PHL)

Application for waivers from NZX Listing Rules 7.8.5(b)

and 7.8.8(b)












NZ RegCo


1



Background

1. The information on which this decision is based is set out in Appendix One to this decision. These

waivers will not apply if that information is not, or ceases to be, full and accurate in all material

respects.

2. The NZX Listing Rules (Rules) to which this decision relates is set out in Appendix Two.

3. Capitalised terms that are not defined in this decision have the meanings given to them in the

Rules.

Waiver from Rule 7.8.5(b) and Rule 7.8.8(b)

Decision

4. Subject to the conditions set out in paragraph 5 below, and on the basis that the information

provided by PHL is complete and accurate in all material respects, NZ RegCo grants PHL a

waiver from Rule 7.8.5(b) and Rule 7.8.8(b) to the extent that these Rules require PHL to

commission an Appraisal Report to accompany its Notice of Meeting for shareholders to consider

a resolution to approve entry into a transaction to:

a. purchase the shares in Chatswood Retirement Limited and Chatswood Lifecare Limited from

vendors that include a Related Party of PHL; and

b. approve an issue of shares to a Related Party of PHL as part of the Purchase Price for the

transaction,

(the Transaction).

5. The waiver in paragraph 4 above is provided on the conditions that:

a. the directors of PHL that are not interested in the Transaction (Non-Interested Directors)

certify to NZ RegCo that in their opinion:

i. the Share issue is in the best interests of, and fair and reasonable to, PHL and all non-

associated shareholders;

ii. the Acquisition is in the best interests of, and fair and reasonable to, PHL and all non-

associated shareholders;

iii. the terms of the Acquisition have been entered into and negotiated on an arm’s length

commercial basis;

iv. PHL was not influenced enter into the Acquisition by the Related Party; and

v. the waivers are in the best interests of, and fair and reasonable to, PHL and all non-

associated shareholders;

with such certificate to fully explain the Non-Interested Directors’ reasons for their opinion;

b. the waiver, its conditions, and implications being disclosed in PHL’s Notice of Meeting;

c. a confirmation letter which sets out the outcome of the independent valuation of Chatswood

as at 31 July 2026 (Independent Valuation) will accompany the Notice of Meeting and

includes:

i. a statement from the independent valuer that he has no conflict of interest that could

affect his ability to provide an unbiased valuation; and


NZ RegCo


2



ii. a statement from the independent valuer outlining his relevant qualifications and

expertise; and

d. NZ RegCo will publish the certificate alongside publication of the waiver decision.

Reasons – Rule 7.8.5(b)

6. The policy behind Rule 7.8.5(b) is to ensure that security holders being asked to vote on

resolutions to which Rule 7.8.5(b) apply, receive the benefit of an independent evaluation that

allows them to understand and scrutinise the merits of that transaction and highlight for

shareholders where Related Parties may be receiving an opportunity which shareholders,

generally, are not receiving.

7. In coming to the decision to provide the waiver from Rule 7.8.5(b) set out in paragraph 4 above,

NZ RegCo has considered that:

a. the policy is not offended where the purpose of the issue of the Consideration Shares is not

complicated or difficult for shareholders to understand;

b. the maximum number of Consideration Shares that may be issued is fixed at 1 million, giving

shareholders certainty as to what they are approving;

c. the issue price for the Consideration Shares is fixed at $0.50 which represented a premium to

the market price of shares when it was agreed. Further detail on this assessment is set out in

the Notice of Meeting. Shareholders can assess the financial implications and fairness of the

Consideration Shares with reference to this assessment;

d. the Notice of Meeting sets out sufficient information to enable shareholders to understand the

effect and consequences of the resolution;

e. PHL’s existing shareholders will be asked to consider the resolution to approve the issue of

Consideration Shares with the knowledge of the waiver sought having been granted;

f. the certification conditions in this waiver provide comfort that the Non-Interested Directors

consider that:

i. the Share issue is in the best interests of, and fair and reasonable to, PHL and all non-

associated shareholders;

ii. the Acquisition is in the best interests of, and fair and reasonable to, PHL and all non-

associated shareholders;

iii. the terms of the Acquisition have been entered into and negotiated on an arm’s length

commercial basis;

iv. PHL was not influenced enter into the Acquisition by the Related Party; and

v. the waivers are in the best interests of, and fair and reasonable to, PHL and all non-

associated shareholders; and

g. there is precedent for this decision.

Reasons – Rule 7.8.8(b)

8. The policy behind Rule 7.8.8(b) is to ensure that shareholders receive the benefit of an

independent evaluation that allows them to understand and scrutinise the merits of the transaction

where there is potential for undue influence by Related Party involvement.

9. In coming to the decision to provide the waiver from Rule 7.8.8(b) set out in paragraph 4 above,

NZ RegCo has considered that:


NZ RegCo


3



a. the Independent Valuation provides an independent, external, benchmark of the market value

of the Acquisition;

b. the outcome of the Independent Valuation together with the detail in the Notice of Meeting

provides PHL’s shareholders with information that allows the shareholders to objectively

assess the merits of the Acquisition to make an informed voting decision;

c. PHL submits, and NZ RegCo has no reason not to accept, that PHL has addressed (or

provided an equivalent for) the specific information requirements of Rule 7.10.2 through the

disclosure in the directors’ certificate and the disclosure on the Independent Valuation in the

Notice of Meeting. PHL submits there is a sufficient information to ensure shareholders can

make an informed decision;

d. entry into, and the terms of, the Acquisition were negotiated on an arm’s length basis and as a

condition of the waivers, the Non-Interested Directors will provide certification to this effect;

e. the Notice of Meeting sets out sufficient information to enable shareholders to assess the

merits and consequences of the Acquisition;

f. PHL’s existing shareholders will be asked to consider the resolution to approve the Acquisition

with the knowledge of the waiver sought having been granted; and

g. the certification conditions in this waiver provide comfort that the Non-Interested Directors

consider that:

i. the Share issue is in the best interests of, and fair and reasonable to, PHL and all non-

associated shareholders;

ii. the Acquisition is in the best interests of, and fair and reasonable to, PHL and all non-

associated shareholders;

iii. the terms of the Acquisition have been entered into and negotiated on an arm’s length

commercial basis;

iv. PHL was not influenced enter into the Acquisition by the Related Party; and

v. The waivers are in the best interests of, and fair and reasonable to, PHL and all non-

associated shareholders;

10. PHL has submitted and NZ RegCo has no reason not to accept that:

a. the Acquisition is appropriate in this context, as the Acquisition has clear strategic merit for

PHL. Since acquiring other aged care facilities, PHL’s core focus has been on lifting

occupancy at its facilities and realising operational efficiencies across its facilities to create a

strong foundation for further growth by acquisition;

b. the Purchase Price represents a $1.2 million (or a 4.58%) discount to the independently

determined current market value of Chatswood, and where the Non-Interested Directors have

certified that the terms are fair and reasonable, shareholders can opine on the fairness of the

Acquisition when considering the Notice of Meeting; and

c. a number of potential acquisitions have been considered by PHL and either disregarded

(particularly due to location, local market demographics or differing views on value) or remain

under investigation. The Non-Interested Directors certify that the Acquisition is in the best

interests of PHL and its non-associated shareholders given its strategic fit with PHL’s existing

portfolio.


NZ RegCo


4



Appendix One

1. Promisia Healthcare Limited (PHL) is a Listed Issuer with its ordinary shares quoted on the NZX

Main Board.

2. PHL operates in the aged care industry and currently operates five residential care facilities and

three retirement villages in three clusters across New Zealand. PHL has a strategy to grow by

undertaking acquisitions of operational retirement villages and aged care facilities.

3. As announced to market on 6 August 2026, PHL has entered into a conditional agreement to

acquire 100% of the shares in two companies, Chatswood Retirement Limited and Chatswood

Lifecare Limited (the Targets) which together own and operate the Chatswood residential care

facility (Chatswood) for total consideration of $25 million (Acquisition).

4. Chatswood is located at 60 Hawford Road, Opawa, Christchurch, within proximity to one of PHL’s

existing aged care facilities. Chatswood comprises of a purpose built and integrated high needs

aged care and retirement village complex spanning 1.2643 hectares. Chatswood is expected to

complement PHL’s existing offering in the region.

5. The Targets are owned in equal proportions by:

a. a family trust associated with Rhonda Sherriff, the Chair of PHL’s Board (Sherriff Interest)

who is a Related Party of PHL; and

b. a family trust associate with Reuben Ennor, (Ennor Interest).

6. The due diligence investigations and negotiations on the terms and conditions of the Acquisition

were conducted by a sub-committee comprising of Non-Interested Directors (excluding the

Related Party). That sub-committee commissioned the Independent Valuation to validate the

Purchase Price and assist the PHL Board in establishing the carrying value of Chatswood for

PHL’s financial statements. The Independent Valuation valued Chatswood at $26.2 million on 31

July 2026, $1.2 million above the Purchase Price. A letter setting out the valuation of the

Chatswood will accompany the Notice of Meeting.

7. The purchase price payable by PHL (Purchase Price) for the Acquisition consists of:

a. $24 million in cash, which will be funded utilising a new core facility and bridge facility with

Bank of New Zealand to the amount of $20 million, and PHL’s cash on hand;

b. an issue of up to 1 million fully paid ordinary shares in PHL (Shares) to the Sherriff Interest at

an issue price of $0.50 per Share (Consideration Shares) on the terms of a subscription

agreement which is summarised in the Notice of Meeting. Rhonda Sherriff does not currently

hold any Shares (either directly or through any Associated Person); and

c. an issue of a convertible note to the Ennor Interest with a face value of $500,000

(Convertible Note) on the terms of a convertible note agreement which is summarised in the

Notice of Meeting. The convertible note matures 12 months after 1 October 2026

(Completion Date) and may be converted into Shares at the option of the Ennor Interest at

any time following maturity at a conversion price of $0.50 per Share. To the extent not

converted, the principal will be repayable in full.

8. If approved by shareholders and the Acquisition becomes unconditional, settlement of the

Transaction will occur on the Completion Date.

Rule Requirements

9. PHL is seeking shareholder approval for the Acquisition under Rules 5.1.1(b) and 5.2.1, and the

issue of Consideration Shares and Convertible Note under Rule 4.2.1, respectively, at its 2026


NZ RegCo


5



Annual Meeting of Shareholders to be held on 27 August 2026. PHL released its notice of

meeting via the NZX Market Announcement Platform on 13 August 2026 (Notice of Meeting).

10. Under Rule 7.8.5(b), because more than 50% of the Consideration Shares are proposed to be

issued to the Sherriff Interest, an Associated Person of a director of PHL, the Notice of Meeting

must be accompanied by an Appraisal Report.

11. The Acquisition is a Material Transaction as the consideration payable by PHL is above 10% of

PHL’s Average Market Capitalisation. The Acquisition is a Material Transaction with a Related

Party under Rule 5.2.1, as Rhonda Sherriff is both associated with the vendor and a director of

PHL. Rule 7.8.8(b) is therefore triggered, and the Notice of Meeting must be accompanied by an

Appraisal Report.

12. PHL is therefore seeking waivers from Rules 7.8.5(b) and 7.8.8(b) to enable PHL to release its

Notice of Meeting without an accompanying Appraisal Report.

13. Further information on the Acquisition and the Consideration Shares can be found in the Notice of

Meeting.


NZ RegCo


6



Appendix Two

Rule 7.8.5

Rule 7.8.5 A notice of meeting to consider a resolution of the nature referred to in Rule 7.8.4

(other than a resolution to permit an issue under Rule 4.7.1) must be accompanied by

an Appraisal Report if:


(...)

(b) more than 50% of the Financial Products to be issued are intended or likely to be

acquired by Directors or Associated Persons of Directors, or

(...)

Rule 7.8.8

Rule 7.8.8 A notice of meeting for the purposes of Rule 5.2.1 must:

(a) be reviewed by NZX in accordance with Rule 7.1,


(b) be accompanied by an Appraisal Report, and


(c) contain such other material as is necessary to enable the holders of Financial

Products entitled to Vote to decide whether the transaction price and terms are

fair.

---

Promisia Healthcare Limited
(Company)

Non-interested Directors Certificate

(Condition of NZX RegCo’s waiver from NZX Listing Rule 7.8.5(b) and 7.8.8(b))


DATED


BACKGROUND


A. Capitalised terms not defined in this certificate shall have the meanings given to them in the

NZX Listing Rules (the Rules).


B. The Company proposes to purchase 100% of the shares in Chatswood Retirement Limited

and Chatswood Lifecare Limited (the Targets) for total consideration of $25 million

(Acquisition). Together, the Targets own and operate the Chatswood Retirement Village

(Facility).


C. A family trust associated with Rhonda Sherriff (the Sherriff Interest), the Chair of the

Company’s board, owns 50% of the shares in each of the Targets.


D. The purchase price payable by the Company (Purchase Price) to complete the Acquisition is:


a. $24 million in cash;


b. an issue of up to 1 million fully paid ordinary shares in the Company (Shares) at an issue

price of $0.50 per Share (Issue Price) to the Sherriff Interest (Share Issue); and


c. an issue of a convertible note to the other shareholder of the Targets (Noteholder) with

a face value of $500,000 and may be converted into Shares at the option of the

Noteholder at any time in the 12-month period following completion of the Acquisition at

a conversion price of $0.50 per Share.


E. Shareholder approval for the Acquisition and the Share Issue is being sought under Rules

5.1.1(b) and 5.2.1, and 4.2.1, respectively. The Company has on or about the date of this

certificate released a notice of meeting of shareholders setting out further particulars of the

Acquisition and the Share Issue, and the shareholder approvals sought (Notice).


F. In a decision of NZX Regulation Limited (NZ RegCo) dated on or around the date of this

certificate (the Decision), NZ RegCo granted the Company a waiver from Rule 7.8.5(b) and

7.8.8(b) to the extent required to allow the Company to enter into the Acquisition without

preparing an Appraisal Report to accompany the Notice (Waiver).


G. The Company applied for the waiver under Rule 7.8.5(b) because:


a. the Share Issue is overall a modest component of the Purchase Price;


b. Rhonda Sherriff will remain a director of the Company following completion of the

Acquisition and the Share Issue will align her interests with those of the Company’s

shareholders;


c. When the Issue Price was set it reflected a premium to the then market price of the

Company’s shares; and


d. the Company is providing shareholders with all material terms of the Share Issue in the

Notice,


Docusign Envelope ID: 606086E6-C74D-8A94-81F4-9D5222C95508

13 August 2026



therefore, an Appraisal Report was considered by the non-interested directors to have

limited value for shareholders given the simple nature of the Share Issue and that on the

information being provided shareholders can make a fully informed voting decision. The

costs of commissioning an appraisal report were therefore considered to outweigh the

benefits.


H. The Company applied for the waiver under Rule 7.8.8(b) because:


a. the Company commissioned an independent valuation of the Facility from CBRE. That

valuation values the Facility at a ~5% premium to the Purchase Price;


b. the non-interested directors are accordingly satisfied that as a result of the Acquisition

an inappropriate transfer of value to the Sherriff Interest is not occurring;


c. the Board’s decision making to pursue the Acquisition and approve the terms of the

Acquisition was undertaken completely independently of Rhonda Sheriff who did not

participate in any relevant Board deliberations or decisions,


therefore, the time and cost of preparing an Appraisal Report, in addition to the Independent

Valuation, was considered disproportionate to any benefit that shareholders may receive

from reviewing an Appraisal Report


I. The Waiver was given on the condition that the non-interested directors of the Company give

this certificate.


CERTIFICATION


We, the undersigned, being all of the directors of the Company who are not interested in the

Acquisition, certify that in our opinion:


1 The Share Issue is in the best interests of, and fair and reasonable to the Company and all

non-associated shareholders of the Company on the following grounds:

1.1 The cash component of the Purchase Price is being funded by new borrowings from

the Bank of New Zealand. The Share Issue allows the Company to fund a modest

proportion of the Purchase Price through equity and give it additional headroom in its

LVR covenant.

1.2 The Issue Price represented a premium to the market price of Shares at the time the

Issue Price was negotiated and agreed. At that time Shares were trading between

$0.42 and $0.46 per Share. The Issue Price remains consistent with the exercise

price for the Company’s quoted warrants (under the ticker code ‘PHLWA’).

1.3 as otherwise outlined in the background section above.

2 The Acquisition is in the best interests of, and fair and reasonable to the Company and all

non-associated shareholders of the Company on the following grounds:

2.1 The Acquisition is consistent with the Company’s growth strategy of growth via

acquiring facilities in regional clusters where operational efficiencies can be realised

and a known high degree of demand for aged care exists.

2.2 The Acquisition is entirely within the ordinary course of the Company’s business,

rather than being a transaction that changes, in any way, the essential nature of the

business.

2.3 The Acquisition will be immediately earnings accretive to the Company and the

Facility has future development potential that could further enhance earnings and the

market value of the Facility.

Docusign Envelope ID: 606086E6-C74D-8A94-81F4-9D5222C95508



2.4 The Purchase Price represents a $1.2 million (or a 4.58%) discount to the

independently determined current market value of the Facility and, despite being

largely funded by debt, will increase the net tangible assets of the Company.

2.5 as otherwise outlined in the background section above.

3 The terms of the Acquisition have been entered into, and negotiated, on an arm’s length

commercial basis, on the following grounds:

3.1 Rhonda Sherriff was not involved in any aspect of Promisia’s decision making in

relation to the Acquisition. In particular, Rhonda Sherriff was not involved in:

3.1.1 the Company’s assessment of the value of the Facility (including the

commissioning of an independent valuation by CBRE);

3.1.2 the Company’s legal, financial, or operational due diligence on the Targets or;

3.1.3 the Board’s consideration of the Acquisition or the negotiation of the sale and

purchase agreement; or

3.1.4 the Board’s decision to enter the sale and purchase agreement and proceed

with the Acquisition.

3.2 The Purchase Price was set by reference to a historic independent valuation of the

Facility (commissioned by the Vendors) and a current valuation (commissioned by the

Company) and dated as at 31 July 2026.

3.3 The Company undertook extensive legal, financial, and operational due diligence

investigations prior to entering into the Acquisition to verify the reasonableness of the

terms and conditions of the Acquisition and the Purchase Price.

3.4 Rhonda Sherriff obtained independent legal advice and negotiated with the Company

strictly in her capacity as a vendor.

3.5 The terms of the Acquisition are considered customary terms for a transaction of this

nature and do not include any novel or extraordinary terms indicating a non-

commercial arrangement.

4 The Company was not influenced to enter into the Acquisition by Rhonda Sherriff on the

following grounds:

4.1 As noted at paragraph 2.1, the Acquisition is consistent with the Company’s stated

growth strategy and will merely represent an expansion of its current ordinary course

of business operations in a locality where it already operates.

4.2 The Company’s due diligence investigations were undertaken exclusively by the

Company’s executive team and external legal advisors. The results of these

investigations were assessed by the non-interested directors.

4.3 Rhonda Sherriff was not involved in the Board’s decision to make an offer to acquire

the Facility, the Board’s consideration of due diligence findings or the Board’s

approval of the Acquisition or its terms.

4.4 The non-interested directors-initiated discussions for the Acquisition on behalf of the

Company based on their extensive industry experience and unanimous view that the

Facility was of a high quality.

5 The Waiver is in the best interests of, and fair and reasonable to, the Company and all non-

associated shareholders of the Company because:

Docusign Envelope ID: 606086E6-C74D-8A94-81F4-9D5222C95508



5.1 the information in the Notice is sufficient to enable equity security holders to make an

informed voting decision on the Acquisition and the Share Issue;

5.2 shareholders will have the opportunity to scrutinise the Acquisition at the Company’s

annual shareholder meeting;

5.3 the Share Issue and the Acquisition is in the best interests of the Company and all of

its shareholders for the reasons set out in paragraph 1 and 2 above;

5.4 the Company was not influenced by Rhonda Sherriff to enter into the transactions

but, rather, entered into the Acquisition after over 8 months of commercial and arms-

length negotiations, as set out in paragraphs 3 and 4 above;

5.5 therefore, the policy behind Rules 7.8.5(b) and 7.8.8(b) are not offended; and

5.6 the granting of the Waiver allows the Acquisition to proceed without incurring the

unnecessary cost of an Appraisal Report.


SIGNED




Tom Brankin, Director Tony Mortensen, Director



Craig Percy, Director Jill Hatchwell, Director




Docusign Envelope ID: 606086E6-C74D-8A94-81F4-9D5222C95508

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.